279 related articles for article (PubMed ID: 16503855)
1. Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.
Ma BB; Chan AT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):383-94. PubMed ID: 16503855
[TBL] [Abstract][Full Text] [Related]
2. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
4. Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Farrell PJ
Nat Clin Pract Oncol; 2005 Jan; 2(1):14-5. PubMed ID: 16264847
[No Abstract] [Full Text] [Related]
5. Nasopharyngeal carcinoma in childhood and adolescence: a single institution's experience with treatment modalities during the last 15 years.
Polychronopoulou S; Kostaridou S; Panagiotou JP; Stefanaki K; Papadakis V; Florentin L; Houlakis M; Christopoulos G; Haidas S
Pediatr Hematol Oncol; 2004; 21(5):393-402. PubMed ID: 15205082
[TBL] [Abstract][Full Text] [Related]
6. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma.
Ma BB; Chan AT
Cancer; 2005 Jan; 103(1):22-31. PubMed ID: 15565580
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.
Lu H; Peng L; Yuan X; Hao Y; Lu Z; Chen J; Cheng J; Deng S; Gu J; Pang Q; Qin J
Cancer Treat Rev; 2009 Jun; 35(4):345-53. PubMed ID: 19211192
[TBL] [Abstract][Full Text] [Related]
8. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
9. Expression of multidrug resistance 1 and glutathione-S-transferase-Pi protein in nasopharyngeal carcinoma.
Chen CL; Sheen TS; Lou IU; Huang AC
Hum Pathol; 2001 Nov; 32(11):1240-4. PubMed ID: 11727264
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
[TBL] [Abstract][Full Text] [Related]
11. Treatment approaches to nasopharyngeal carcinoma: a review.
Caponigro F; Longo F; Ionna F; Perri F
Anticancer Drugs; 2010 Jun; 21(5):471-7. PubMed ID: 20124988
[TBL] [Abstract][Full Text] [Related]
12. Advances in nasopharyngeal carcinoma.
Guigay J
Curr Opin Oncol; 2008 May; 20(3):264-9. PubMed ID: 18391624
[TBL] [Abstract][Full Text] [Related]
13. A novel application of plasma and cerebrospinal fluid level of epstein barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report.
Ma AT; Ma BB; Teo PM; Chan AT
Oncology; 2008; 74(1-2):119-22. PubMed ID: 18547967
[TBL] [Abstract][Full Text] [Related]
14. Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.
Loong HH; Ma BB; Chan AT
Hematol Oncol Clin North Am; 2008 Dec; 22(6):1267-78, x. PubMed ID: 19010273
[TBL] [Abstract][Full Text] [Related]
15. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
17. [Nasopharyngeal carcinomas: from biology to clinic].
Rivera S; Keryer C; Busson P; Maingon P
Cancer Radiother; 2005 Feb; 9(1):55-68. PubMed ID: 15804621
[TBL] [Abstract][Full Text] [Related]
18. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival.
Lin JC; Chen KY; Wang WY; Jan JS; Liang WM; Tsai CS; Wei YH
J Clin Oncol; 2001 May; 19(10):2607-15. PubMed ID: 11352952
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of medical therapy upon undifferentiated nasopharyngeal carcinoma: analysis of 149 cases].
Chen M; Lin S; Zheng W
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1488-9. PubMed ID: 16200771
[TBL] [Abstract][Full Text] [Related]
20. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature.
Langendijk JA; Leemans CR; Buter J; Berkhof J; Slotman BJ
J Clin Oncol; 2004 Nov; 22(22):4604-12. PubMed ID: 15542811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
